BridgeBio reports exploratory PROPEL 3 data showing wider clinical trends for oral infigratinib

Tyra Biosciences declares positive Phase 2 results for oral dabogratinib in bladder cancer

Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart

Kazia Therapeutics doses first patient in paediatric AT/RT study

Fusion Antibodies secures Canadian patent for OptiMAL

Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities

Biophytis expands BIO101 obesity study to assess weight regain

THX Pharma secures European patent for Batten-1 in juvenile Batten disease

Orphalan commences Phase 3 study of trientine therapy in Wilson disease

ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year

Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis

Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART

PT Prodia Diacro Laboratories receives Southeast Asian CRO Customer Value Leadership recognition from Frost & Sullivan

CorrectSequence Therapeutics reports new research showing tBE-mediated base editing therapy achieves durable remission in SCD and TDT across different genetic backgrounds

Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer